Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer Academic Article uri icon

Overview

MeSH Major

  • Head and Neck Neoplasms
  • Palliative Care

abstract

  • Sorafenib and temsirolimus appear to be an active combination in patients with radioactive iodine-refractory thyroid carcinoma, especially in patients who received no prior treatment compared with historic data from single-agent sorafenib. Activity is also observed in patients who previously received sorafenib. This regimen warrants further investigation. Cancer 2017;123:4114-4121. © 2017 American Cancer Society.

publication date

  • November 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5650535

Digital Object Identifier (DOI)

  • 10.1002/cncr.30861

PubMed ID

  • 28662274

Additional Document Info

start page

  • 4114

end page

  • 4121

volume

  • 123

number

  • 21